Clinical Cancer Research Grants Frontiers in Basic Cancer Research
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Adjei, A. A.
Right arrow Articles by Kaufmann, S. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Adjei, A. A.
Right arrow Articles by Kaufmann, S. H.
Clinical Cancer Research Vol. 6, 2318-2325, June 2000
© 2000 American Association for Cancer Research

Molecular Oncology, Markers, Clinical Correlates

Comparison of Potential Markers of Farnesyltransferase Inhibition1

Alex A. Adjei2, Jenny N. Davis, Charles Erlichman, Phyllis A. Svingen and Scott H. Kaufmann

Divisions of Medical Oncology [A. A. A., C. E.] and Oncology Research [J. N. D., P. A. S., S. H. K.], Mayo Clinic and Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Graduate School [S. H. K.], Rochester, Minnesota 55905

Farnesyltransferase inhibitors (FTIs) were developed to target abnormal signaling pathways that are commonly activated in neoplastic cells. Five FTIs have recently undergone Phase I testing; and two are currently in Phase II clinical trials. As part of the development of these agents, there has been interest in determining their cellular effects in the clinical setting. Several approaches have been proposed, including measurement of FT enzymatic activity, evaluation of the processing of FT polypeptide substrates, and assessment of the accumulation of p21waf1. In the present study, a number of these assays have been compared in four cultured human neoplastic cell lines of different histology (A549, HCT116, BxPC-3, and MCF-7) after treatment with the nonpeptidomimetic FTI SCH66336 and the peptidomimetic inhibitor FTI-277. Immunoblotting studies failed to demonstrate a mobility shift in ras proteins or increased accumulation of p21waf1 after treatment with these agents. In contrast, drug-induced increases in the slower migrating, unprocessed species of the chaperone protein HDJ-2 and the intranuclear intermediate filament protein lamin A were detected in all four cell lines after treatment with either agent. Unprocessed forms of both polypeptides accumulated in noncycling as well as cycling cells. The precursor peptide that is present in prelamin A but absent from mature lamin A could be readily detected by immunohistochemistry in noncycling cells with a peptide-specific antiserum. Our results indicate that unprocessed HDJ-2 and prelamin A should be suitable markers of FT inhibition in clinical samples.




This article has been cited by other articles:


Home page
 Proc. Natl. Acad. Sci. USAHome page
B. C. Capell, M. Olive, M. R. Erdos, K. Cao, D. A. Faddah, U. L. Tavarez, K. N. Conneely, X. Qu, H. San, S. K. Ganesh, et al.
A farnesyltransferase inhibitor prevents both the onset and late progression of cardiovascular disease in a progeria mouse model
PNAS, October 14, 2008; 105(41): 15902 - 15907.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
T. Raz, V. Nardi, M. Azam, J. Cortes, and G. Q. Daley
Farnesyl transferase inhibitor resistance probed by target mutagenesis
Blood, September 15, 2007; 110(6): 2102 - 2109.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
R. E. Marks, A. W. Ho, C. Robbel, T. Kuna, S. Berk, and T. F. Gajewski
Farnesyltransferase inhibitors inhibit T-cell cytokine production at the posttranscriptional level
Blood, September 15, 2007; 110(6): 1982 - 1988.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. W. Kieran, R. J. Packer, A. Onar, S. M. Blaney, P. Phillips, I. F. Pollack, J. R. Geyer, S. Gururangan, A. Banerjee, S. Goldman, et al.
Phase I and Pharmacokinetic Study of the Oral Farnesyltransferase Inhibitor Lonafarnib Administered Twice Daily to Pediatric Patients With Advanced Central Nervous System Tumors Using a Modified Continuous Reassessment Method: A Pediatric Brain Tumor Consortium Study
J. Clin. Oncol., July 20, 2007; 25(21): 3137 - 3143.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
J. E. Lancet, I. Gojo, J. Gotlib, E. J. Feldman, J. Greer, J. L. Liesveld, L. M. Bruzek, L. Morris, Y. Park, A. A. Adjei, et al.
A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia
Blood, February 15, 2007; 109(4): 1387 - 1394.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
C.-C. Wang, Y.-P. Liao, P. S. Mischel, K. S. Iwamoto, N. A. Cacalano, and W. H. McBride
HDJ-2 as a Target for Radiosensitization of Glioblastoma Multiforme Cells by the Farnesyltransferase Inhibitor R115777 and the Role of the p53/p21 Pathway.
Cancer Res., July 1, 2006; 66(13): 6756 - 6762.
[Abstract] [Full Text] [PDF]

Home page
 ScienceHome page
L. G. Fong, D. Frost, M. Meta, X. Qiao, S. H. Yang, C. Coffinier, and S. G. Young
A Protein Farnesyltransferase Inhibitor Ameliorates Disease in a Mouse Model of Progeria
Science, March 17, 2006; 311(5767): 1621 - 1623.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
D. McClintock, L. B. Gordon, and K. Djabali
Hutchinson-Gilford progeria mutant lamin A primarily targets human vascular cells as detected by an anti-Lamin A G608G antibody
PNAS, February 14, 2006; 103(7): 2154 - 2159.
[Abstract] [Full Text] [PDF]

Home page
 J. Lipid Res.Home page
A. D. Basso, P. Kirschmeier, and W. R. Bishop
Thematic review series: Lipid Posttranslational Modifications. Farnesyl transferase inhibitors
J. Lipid Res., January 1, 2006; 47(1): 15 - 31.
[Abstract] [Full Text] [PDF]

Home page
 J. Lipid Res.Home page
S. G. Young, L. G. Fong, and S. Michaelis
Thematic Review Series: Lipid Posttranslational Modifications. Prelamin A, Zmpste24, misshapen cell nuclei, and progeria--new evidence suggesting that protein farnesylation could be important for disease pathogenesis
J. Lipid Res., December 1, 2005; 46(12): 2531 - 2558.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
T. F. Cloughesy, J. Kuhn, H. I. Robins, L. Abrey, P. Wen, K. Fink, F. S. Lieberman, M. Mehta, S. Chang, A. Yung, et al.
Phase I Trial of Tipifarnib in Patients With Recurrent Malignant Glioma Taking Enzyme-Inducing Antiepileptic Drugs: A North American Brain Tumor Consortium Study
J. Clin. Oncol., September 20, 2005; 23(27): 6647 - 6656.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
N. M.G.M. Appels, J. H. Beijnen, and J. H.M. Schellens
Development of Farnesyl Transferase Inhibitors: A Review
Oncologist, September 1, 2005; 10(8): 565 - 578.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
B. Zhang, J. Groffen, and N. Heisterkamp
Resistance to farnesyltransferase inhibitors in Bcr/Abl-positive lymphoblastic leukemia by increased expression of a novel ABC transporter homolog ATP11a
Blood, August 15, 2005; 106(4): 1355 - 1361.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
L. M. Bruzek, J. N. Poynter, S. H. Kaufmann, and A. A. Adjei
Characterization of a Human Carcinoma Cell Line Selected for Resistance to the Farnesyl Transferase Inhibitor 4-(2-(4-(8-Chloro-3,10-dibromo-6,11-dihydro-5H-benzo-(5,6)-cyclohepta(1,2-b)-pyridin-11(R)-yl)-1-piperidinyl)-2-oxo-ethyl)-1-piperidinecarboxamide (SCH66336)
Mol. Pharmacol., August 1, 2005; 68(2): 477 - 486.
[Abstract] [Full Text] [PDF]

Home page
 Hum Mol GenetHome page
C. Capanni, E. Mattioli, M. Columbaro, E. Lucarelli, V. K. Parnaik, G. Novelli, M. Wehnert, V. Cenni, N. M. Maraldi, S. Squarzoni, et al.
Altered pre-lamin A processing is a common mechanism leading to lipodystrophy
Hum. Mol. Genet., June 1, 2005; 14(11): 1489 - 1502.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
C.-L. Gau, J. Kato-Stankiewicz, C. Jiang, S. Miyamoto, L. Guo, and F. Tamanoi
Farnesyltransferase inhibitors reverse altered growth and distribution of actin filaments in Tsc-deficient cells via inhibition of both rapamycin-sensitive and -insensitive pathways
Mol. Cancer Ther., June 1, 2005; 4(6): 918 - 926.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
G. K. Dy, L. M. Bruzek, G. A. Croghan, S. Mandrekar, C. Erlichman, P. Peethambaram, H. C. Pitot, L. J. Hanson, J. M. Reid, A. Furth, et al.
A Phase I Trial of the Novel Farnesyl Protein Transferase Inhibitor, BMS-214662, in Combination with Paclitaxel and Carboplatin in Patients with Advanced Cancer
Clin. Cancer Res., March 1, 2005; 11(5): 1877 - 1883.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
Y. Kho, S. C. Kim, C. Jiang, D. Barma, S. W. Kwon, J. Cheng, J. Jaunbergs, C. Weinbaum, F. Tamanoi, J. Falck, et al.
A tagging-via-substrate technology for detection and proteomics of farnesylated proteins
PNAS, August 24, 2004; 101(34): 12479 - 12484.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
M. Alsina, R. Fonseca, E. F. Wilson, A. N. Belle, E. Gerbino, T. Price-Troska, R. M. Overton, G. Ahmann, L. M. Bruzek, A. A. Adjei, et al.
Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma
Blood, May 1, 2004; 103(9): 3271 - 3277.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. Sun, J. Ohkanda, D. Coppola, H. Yin, M. Kothare, B. Busciglio, A. D. Hamilton, and S. M. Sebti
Geranylgeranyltransferase I Inhibitor GGTI-2154 Induces Breast Carcinoma Apoptosis and Tumor Regression in H-Ras Transgenic Mice
Cancer Res., December 15, 2003; 63(24): 8922 - 8929.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
V. Ramamurthy, M. Roberts, F. van den Akker, G. Niemi, T. A. Reh, and J. B. Hurley
AIPL1, a protein implicated in Leber's congenital amaurosis, interacts with and aids in processing of farnesylated proteins
PNAS, October 28, 2003; 100(22): 12630 - 12635.
[Abstract] [Full Text] [PDF]

Home page
 JCBHome page
C. P. Maske, M. S. Hollinshead, N. C. Higbee, M. O. Bergo, S. G. Young, and D. J. Vaux
A carboxyl-terminal interaction of lamin B1 is dependent on the CAAX endoprotease Rce1 and carboxymethylation
J. Cell Biol., September 29, 2003; 162(7): 1223 - 1232.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
C. Selleri, J. P. Maciejewski, N. Montuori, P. Ricci, V. Visconte, B. Serio, L. Luciano, and B. Rotoli
Involvement of nitric oxide in farnesyltransferase inhibitor-mediated apoptosis in chronic myeloid leukemia cells
Blood, August 15, 2003; 102(4): 1490 - 1498.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. A. Adjei, G. A. Croghan, C. Erlichman, R. S. Marks, J. M. Reid, J. A. Sloan, H. C. Pitot, S. R. Alberts, R. M. Goldberg, L. J. Hanson, et al.
A Phase I Trial of the Farnesyl Protein Transferase Inhibitor R115777 in Combination with Gemcitabine and Cisplatin in Patients with Advanced Cancer
Clin. Cancer Res., July 1, 2003; 9(7): 2520 - 2526.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
Y. Shi, J. Gera, J.-h. Hsu, B. Van Ness, and A. Lichtenstein
Cytoreductive Effects of Farnesyl Transferase Inhibitors on Multiple Myeloma Tumor Cells
Mol. Cancer Ther., June 1, 2003; 2(6): 563 - 572.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. A. Adjei, A. Mauer, L. Bruzek, R. S. Marks, S. Hillman, S. Geyer, L. J. Hanson, J. J. Wright, C. Erlichman, S. H. Kaufmann, et al.
Phase II Study of the Farnesyl Transferase Inhibitor R115777 in Patients With Advanced Non-Small-Cell Lung Cancer
J. Clin. Oncol., May 1, 2003; 21(9): 1760 - 1766.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
A. Nakajima, T. Tauchi, M. Sumi, W. R. Bishop, and K. Ohyashiki
Efficacy of SCH66336, a Farnesyl Transferase Inhibitor, in Conjunction with Imatinib against BCR-ABL-positive Cells
Mol. Cancer Ther., March 1, 2003; 2(3): 219 - 224.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
R. B. Lobell, D. Liu, C. A. Buser, J. P. Davide, E. DePuy, K. Hamilton, K. S. Koblan, Y. Lee, S. Mosser, S. L. Motzel, et al.
Preclinical and Clinical Pharmacodynamic Assessment of L-778,123, a Dual Inhibitor of Farnesyl:Protein Transferase and Geranylgeranyl:Protein Transferase Type-I
Mol. Cancer Ther., July 1, 2002; 1(9): 747 - 758.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
V. Smith, M. G. Rowlands, E. Barrie, P. Workman, and L. R. Kelland
Establishment and Characterization of Acquired Resistance to the Farnesyl Protein Transferase Inhibitor R115777 in a Human Colon Cancer Cell Line
Clin. Cancer Res., June 1, 2002; 8(6): 2002 - 2009.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
B. Zhang, G. C. Prendergast, and R. G. Fenton
Farnesyltransferase Inhibitors Reverse Ras-mediated Inhibition of Fas Gene Expression
Cancer Res., January 1, 2002; 62(2): 450 - 458.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
L. R. Kelland, V. Smith, M. Valenti, L. Patterson, P. A. Clarke, S. Detre, D. End, A. J. Howes, M. Dowsett, P. Workman, et al.
Preclinical Antitumor Activity and Pharmacodynamic Studies with the Farnesyl Protein Transferase Inhibitor R115777 in Human Breast Cancer
Clin. Cancer Res., November 1, 2001; 7(11): 3544 - 3550.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
J. E. Karp, J. E. Lancet, S. H. Kaufmann, D. W. End, J. J. Wright, K. Bol, I. Horak, M. L. Tidwell, J. Liesveld, T. J. Kottke, et al.
Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial
Blood, June 1, 2001; 97(11): 3361 - 3369.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. A. Adjei, J. N. Davis, L. M. Bruzek, C. Erlichman, and S. H. Kaufmann
Synergy of the Protein Farnesyltransferase Inhibitor SCH66336 and Cisplatin in Human Cancer Cell Lines
Clin. Cancer Res., May 1, 2001; 7(5): 1438 - 1445.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2000 by the American Association for Cancer Research.